The counterattack of BSM aims Samjin, United, JW and Ildong

Published: 2015-05-12 09:36:58

Updated: 2015-05-12 09:36:58

Keeping the top position in prescriptions, Baraclude (BMS) has started to counterattack.

According to the industry concerned, Bristol-Myers Squibb Holdings Island owning the permission of the hepatitis type B treatment, Baraclude, has recently filed an appellate trial for the trial decision against 4 domestic pharmaceutical companies

Pharmaceutical companies as claimees are Samjin Pharm, Unit...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.